Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Hodgkin Disease 48Recurrence 13Lymphoma 12Lymphoma, T-Cell, Cutaneous 10Lymphoma, T-Cell, Peripheral 9Mycosis Fungoides 8Lymphoma, T-Cell 7Lymphoma, Large-Cell, Anaplastic 7Sezary Syndrome 5Lymphoma, Non-Hodgkin 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Immunoblastic Lymphadenopathy 4Enteropathy-Associated T-Cell Lymphoma 4Neoplasms, Germ Cell and Embryonal 3Lymphomatoid Papulosis 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Leukemia 3Testicular Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphatic Diseases 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Large Granular Lymphocytic 2Hematologic Neoplasms 2Carcinoma, Embryonal 2

Interventions

midostaurin 2obatoclax 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Thalidomide 1Ranitidine 1Phlebotomy 1Imatinib Mesylate 1Ibuprofen 1Everolimus 1Diphenhydramine 1Dexamethasone 1Denosumab 1Dasatinib 1Cladribine 1Calcium Dobesilate 1Brentuximab Vedotin 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mastocytosis, Systemic × Brentuximab Vedotin × Clear all
NCT01807598 2019-01-29

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Stanford University

Phase 2 Completed
10 enrolled 14 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡